Common CMC (Quality) Issues and How to Avoid Them Part I (12of16) Generic Drugs Forum
Рет қаралды 6,777
Күн бұрынSimin Hassannejad Tabasi and Pei-I Chu from the CDER Office of Pharmaceutical Quality discuss common drug product quality issues and CMC issues for manufacturing process and facility reviews.
Hassannejad Tabasi discusses ANDA applications related to Solid Oral Drug Products (SODP), identifies the most common areas of quality gaps in the ANDA submission, and possible resolutions.
Chu shares the key elements of process and facility review, commonly seen deficiencies for various dosage forms, and considerations for information to be included in the submission.
Learn more at www.fda.gov/dr...
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming training and free continuing education credits: www.fda.gov/cd...
CDER SBIA 2020 Playlist: • 2020 CDER Small Busine...
LinkedIn: / cder-small-business-an...
Training resources: www.fda.gov/cd...
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.go...
Email: CDERSBIA@fda.hhs.gov
Phone: (301) 796-6707 I (866) 405-5367
U.S. Food and Drug Administration
Рет қаралды 3,1 М.
U.S. Food and Drug Administration
Рет қаралды 23 М.
НТК Show
Рет қаралды 197 М.
U.S. Food and Drug Administration
Рет қаралды 10 М.
U.S. Food and Drug Administration
Рет қаралды 694
U.S. Food and Drug Administration
Рет қаралды 12 М.
U.S. Food and Drug Administration
Рет қаралды 3,6 М.
U.S. Food and Drug Administration
Рет қаралды 1,2 М.
U.S. Food and Drug Administration
Рет қаралды 524
U.S. Food and Drug Administration
Рет қаралды 9 М.
U.S. Food and Drug Administration
Рет қаралды 331
U.S. Food and Drug Administration
Рет қаралды 516